David Steinberg
Stock Analyst at Jefferies
(2.93)
# 1,672
Out of 5,090 analysts
33
Total ratings
64%
Success rate
26.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Steinberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHC Bausch Health Companies | Downgrades: Hold | $12 → $8 | $7.30 | +9.59% | 7 | Feb 6, 2025 | |
| PRGO Perrigo Company | Upgrades: Buy | $45 → $63 | $13.44 | +368.75% | 8 | Sep 30, 2021 | |
| SUPN Supernus Pharmaceuticals | Upgrades: Buy | $25 → $40 | $45.14 | -11.39% | 11 | Apr 13, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $151 → $188 | $168.20 | +11.77% | 5 | Oct 9, 2020 | |
| OCUL Ocular Therapeutix | Initiates: Buy | $8 | $12.37 | -35.33% | 1 | Mar 17, 2020 | |
| SVRA Savara | Initiates: Buy | $20 | $6.51 | +207.22% | 1 | Sep 22, 2017 |
Bausch Health Companies
Feb 6, 2025
Downgrades: Hold
Price Target: $12 → $8
Current: $7.30
Upside: +9.59%
Perrigo Company
Sep 30, 2021
Upgrades: Buy
Price Target: $45 → $63
Current: $13.44
Upside: +368.75%
Supernus Pharmaceuticals
Apr 13, 2021
Upgrades: Buy
Price Target: $25 → $40
Current: $45.14
Upside: -11.39%
Jazz Pharmaceuticals
Oct 9, 2020
Maintains: Buy
Price Target: $151 → $188
Current: $168.20
Upside: +11.77%
Ocular Therapeutix
Mar 17, 2020
Initiates: Buy
Price Target: $8
Current: $12.37
Upside: -35.33%
Savara
Sep 22, 2017
Initiates: Buy
Price Target: $20
Current: $6.51
Upside: +207.22%